Aim: The aim of the present study was to study the efficacy of amantadine in improving cognitive dysfunction in patients with severe traumatic brain injury. Methods: This is an observational study conducted in a tertiary care hospital in Telangana state, India. We obtained informed consent from the legal representative or next of kin or relative for each patient who enrolled in this study with their willingness and have their data published. 70 patients were included in the study. The patients who survived severe TBI were observed for 2 months with a Full Outline of Unresponsiveness (FOUR) score. Results: Over the course of the 4-week treatment and follow up period, there was a gradual and noticeable enhancement in cognitive function, as seen by substantial improvements in the FOUR score, DRS, and GOS. The negative reactions included spasticity, agitation, vomiting, rash, restlessness, diarrhea, increased liver function tests, generalized tonic clonic seizures (GTCS), constipation, focal convulsions, and nausea. Conclusion: Amantadine administration is both safe and linked to rapid cognitive enhancement in individuals with stagnant or deteriorating cognitive function after severe traumatic brain injury (TBI). This improvement serves as the basis for achieving functional independence.